Abstract
BackgroundAt 2 yrs, rituximab (RTX) plus methotrexate (MTX) has been shown to inhibit progressive joint damage (PJD) in patients (pts) with RA and an inadequate response to TNF inhibitors (TNF-IR).1...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have